Last reviewed · How we verify
DoxyPEP
DoxyPEP is doxycycline used as a post-exposure prophylaxis to prevent sexually transmitted infections by inhibiting bacterial protein synthesis.
DoxyPEP is doxycycline used as a post-exposure prophylaxis to prevent sexually transmitted infections by inhibiting bacterial protein synthesis. Used for Post-exposure prophylaxis for sexually transmitted infections (chlamydia, gonorrhea, syphilis).
At a glance
| Generic name | DoxyPEP |
|---|---|
| Also known as | doxycycline PEP |
| Sponsor | Chinese University of Hong Kong |
| Drug class | Tetracycline antibiotic |
| Target | Bacterial 30S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Sexual Health |
| Phase | FDA-approved |
Mechanism of action
DoxyPEP leverages doxycycline's broad-spectrum antimicrobial activity as a preventive strategy taken after potential exposure to sexually transmitted pathogens. The tetracycline antibiotic inhibits bacterial protein synthesis, reducing the establishment of infections including chlamydia, gonorrhea, and syphilis when administered shortly after sexual exposure.
Approved indications
- Post-exposure prophylaxis for sexually transmitted infections (chlamydia, gonorrhea, syphilis)
Common side effects
- Nausea
- Photosensitivity
- Esophageal irritation
- Vaginal yeast infection
Key clinical trials
- The Efficacy of Doxycycline Post Exposure Prophylaxis for Preventing STIs Among MSM in Bangkok, Thailand. (PHASE4)
- Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections (PHASE4)
- Periodic Presumptive Treatment vs. doxyPEP for STI Control in Kenyan MSM (PHASE4)
- Improving HIV Prevention and Substance Use Post-Sexual Assault Services (NA)
- Superiority of On-demand PrEP Versus PEP on Using Doxycycline for Preventing STI in MSM (PHASE4)
- STI Prophylaxis and Emergence of Antimicrobial Resistance
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DoxyPEP CI brief — competitive landscape report
- DoxyPEP updates RSS · CI watch RSS
- Chinese University of Hong Kong portfolio CI